Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 16/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 15/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5646483 | 0.97 | SLC6A4 (0.42) | SLC6A3SLC6A4SLC6A2ALDH1A1L3MBTL1 | |
| SCHEMBL5642584 | 0.93 | ALDH1A1 (0.38) | SLC6A3SLC6A4SLC6A2ALDH1A1L3MBTL1 | |
| SCHEMBL14347875 | 0.84 | SLC6A4 (0.47) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL8354603 | 0.81 | SLC6A4 (0.44) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL11634132 | 0.80 | SLC6A4 (0.48) | SLC6A3SLC6A4SLC6A2POLB | |
| SCHEMBL5645135 | 0.80 | POLB (0.41) | SLC6A3SLC6A4SLC6A2ALDH1A1L3MBTL1 | |
| SCHEMBL11111686 | 0.79 | SLC6A4 (0.42) | SLC6A3SLC6A4SLC6A2 | |
| Hydrochloric Acid SCHEMBL6477899 | 0.78 | SLC6A4 (0.41) | SLC6A3SLC6A4SLC6A2 | |
| Hydrochloric Acid SCHEMBL11105518 | 0.78 | SLC6A4 (0.61) | SLC6A3SLC6A4SLC6A2ALDH1A1 | |
| SCHEMBL9116950 | 0.77 | SLC6A4 (0.53) | SLC6A3SLC6A4SLC6A2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040254158-A1 | Anticoagulants; atherosclerosis; strokes; thrombosis; cardiovascular disorders | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-16 | — | — | US | claimed |
| US-7312214-B2 | 1, 1-disubstituted cycloalkyl derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-20040254158-A1 | Anticoagulants; atherosclerosis; strokes; thrombosis; cardiovascular disorders | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254158-A1 | Anticoagulants; atherosclerosis; strokes; thrombosis; cardiovascular disorders | SERPINC1, PCSK9, PLAT | SLC6A3 1899/4885SLC6A4 2705/4885SLC6A2 2844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.